A decrease of the butyrate-producing species <i>Roseburia hominis</i> and <i>Faecalibacterium prausnitzii</i> defines dysbiosis in patients with ulcerative colitisKathleen Machiels, Séverine Vermeire, Paul Rutgeerts et al.|Gut|2013Cited by 1.9k
The Effects of Infliximab Therapy on Health-Related Quality of Life in Ulcerative Colitis PatientsBrian G. Feagan, Stephen B. Hanauer, Jewel Johanns et al.|The American Journal of Gastroenterology|2007Cited by 178
Mucosal expression by B7-positive cells of the 60-kilodalton heat-shock protein in inflammatory bowel diseaseWilly Peetermans, Karel Geboes, Geert D’Haens et al.|Gastroenterology|1995Cited by 53
Long-term Safety of Vedolizumab for the Treatment of Ulcerative Colitis or Crohnʼs DiseaseJean‐Frédéric Colombel, Brian G. Feagan, Serap Sankoh et al.|The American Journal of Gastroenterology|2013Cited by 22
P300 Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double-blind, placebo-controlled Phase2b study of ustekinumab in patients with moderately to severely active Crohn's diseaseB. Feagan, B E Sands, Christopher Gasink et al.|Journal of Crohn s and Colitis|2012Cited by 9